pharma · Obesity · Type 2 diabetes
NovoThirteen
NovoThirteen is a pharma organization headquartered in Bagsværd, JP. Primary therapeutic focus areas include Obesity, Type 2 diabetes, Type 2 Diabetes, Mild cognitive impairment (MCI) or mild dementia, both of the Alzhei
Company details
- Status
- Public
- HQ
- Bagsværd, JP
- Programs
- 94
- Drugs
- 67
- Patents
- 0
Quick answer
NovoThirteen is a pharma organization headquartered in Bagsværd, JP. Primary therapeutic focus areas include Obesity, Type 2 diabetes, Type 2 Diabetes, Mild cognitive impairment (MCI) or mild dementia, both of the Alzheimer’s type, Overweight and obesity. NovaPharmaNews links 94 clinical program(s), 9 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 3 (43), phase 1 (35), phase 2 (13).
Company snapshot
NovoThirteen maintains 94 tracked programs across Obesity, Type 2 diabetes, Type 2 Diabetes, Mild cognitive impairment (MCI) or mild dementia, both of the Alzheimer’s type, Overweight and obesity, Diabetes mellitus type 1, Sickle cell disease, Overweight or obesity, and knee osteoarthritis, Non-alcoholic steatohepatitis (NASH), Participants with transthyretin amyloid cardiomyopathy (ATTR CM), Hear
- 8 approved product(s) across US/EU regulatory metadata.
- 94 active pipeline program(s) linked via ClinicalTrials.gov.
- 94 trial update(s) in the last 12 months.
Public regulatory, clinical, patent, and corporate records for NovoThirteen. Not investment advice.
Top assets
Lead pipeline drugs
- approved
- Marketed / approved
- Marketed / approved
- Marketed / approved
Active clinical programs
- Phase 3
- Phase 3
- Phase 3
- Phase 3
Momentum
Proprietary activity score for NovoThirteen.
Signal breakdown
- Clinical trials
- Nova articles
- Patents filed
- FDA actions
- SEC filings
- Conference presentations
- Pipeline advances
Competitor landscape
Therapeutic-area overlap peers from registry and pipeline signals.
- Peer + 0 momentum
- Peer + 0 momentum
Recent activity
Latest pipeline, patent, and corporate events for NovoThirteen.
- Clinical update
- Clinical update
- Clinical update
- Clinical update
- Clinical update
Quick answers
Common questions about this sponsor — for analysts and search.
-
What is NovoThirteen?
-
Is NovoThirteen publicly traded?
-
What drugs does NovoThirteen develop or market?
-
What are the latest developments for NovoThirteen?
-
What therapeutic areas does NovoThirteen focus on?
Therapeutic focus
Therapeutic area distribution
Pipeline concentration by therapeutic area from linked clinical programs.